Eko.Ai Pte Ltd. D/B/A Us2.Ai
About Eko.Ai Pte Ltd. D/B/A Us2.Ai
Us2.ai, formerly known as Eko.ai, is a Singapore-based healthcare AI company dedicated to transforming cardiovascular diagnostics through advanced machine learning. The company’s core offering is a platform that automates the analysis of echocardiograms, which are ultrasound images of the heart. This technology processes both 2D and Doppler views to generate comprehensive, structured echo reports, including measurements, disease detection, and clinical findings, often in a matter of minutes and with minimal to zero manual intervention.
For physicians, Us2.ai’s solutions, such as Us2.v1, Us2.v2, and Echo Copilot, are designed to significantly enhance workflow efficiency, improve diagnostic accuracy, and reduce inter-operator variability in echocardiogram interpretation. The platform is FDA-cleared and CE Marked, with clinical validation demonstrating its ability to provide expert-level analysis. By automating the traditionally time-consuming and labor-intensive process of echocardiography analysis, Us2.ai aims to democratize access to high-quality cardiac diagnostics globally, supporting the timely detection and management of various cardiovascular conditions, including heart failure, aortic stenosis, cardiac amyloidosis, pulmonary hypertension, and hypertrophic cardiomyopathy, and aiding in cardiovascular research and clinical trials.
Focus Areas
Business Intelligence
| Key Investors | IHH Healthcare, Heal Partners, Sequoia India (now Peak XV Partners), EDBI, Pappas Capital, Partech Ventures, SGInnovate, Bfa Global Investors, East Post Road Ventures, FJ Labs |
| Partnerships | Fujifilm, deepc, Harrison.ai, Merative Merge, Aidoc, Viz.ai, AstraZeneca, Janssen, Duke University, Brigham & Women's Hospital, Lenus Health |
| Acquisitions | None |
| Technology | Deep learning pattern recognition, AI-powered echocardiography analysis, cloud-native, integrates with ultrasound devices and PACS/CVIS/EMR, federated learning, zero-click automation, vendor-neutral |
| FDA Clearances | 3+ cleared products (estimated) |
What Physicians Need to Know
Us2.ai significantly streamlines your workflow by automating echocardiogram analysis and reporting, reducing interpretation time by up to 70% and minimizing inter-operator variability. This allows for faster diagnoses, increased patient throughput, and more time for direct patient care. The platform provides comprehensive, guideline-directed reports with editable AI outputs and transparent visual overlays, ensuring you maintain clinical oversight while benefiting from AI-driven insights. Its ability to detect conditions like cardiac amyloidosis automatically can aid in earlier diagnosis of often-missed diseases. Consider leveraging Us2.ai for standardizing echo reporting across your institution and for supporting clinical research initiatives.
Us2.ai is designed for flexible integration, being vendor-agnostic and compatible with all echo devices and PACS manufacturers. It connects to ultrasound devices and PACS, processing DICOM images, and can deliver results and reports via browser and/or send them to PACS or EMR systems. Deployment options include secure region-specific AWS cloud servers or on-premise solutions. The system operates as an additive layer, meaning your existing workflow continues unaffected even if the service is unavailable, and pilots can be run in parallel processing mode without production risk. Partnerships with platforms like Aidoc's aiOS and integration with ultrasound devices like Fujifilm's LISENDO 880 further enhance its integration capabilities.
What the Web Says
Us2.ai (formerly Eko.ai Pte Ltd.) is a Singapore-based healthcare AI company that provides FDA-cleared, AI-powered echocardiography analysis software. The software aims to automate measurements, enhance accuracy, and improve workflow efficiency for cardiologists and sonographers. Reviews indicate positive perceptions from clinicians who have piloted the solution, noting improvements in measurement accuracy and faster reporting times.
Overall: PositiveStrengths
- Enhances measurement accuracy and consistency.
- Improves workflow efficiency and reduces reporting time significantly (e.g., 70% faster reporting, structured report in seconds).
- Reduces manual work and sonographer fatigue, allowing more focus on patients.
- Vendor-neutral, operating on standard DICOM across major ultrasound platforms and handheld POCUS devices.
- FDA 510(k) cleared and CE Marked, with multiple peer-reviewed publications validating its technology.
- Seamless integration into existing clinical workflows and systems like Merge Cardio.
Limitations
- Initial technical challenges with integration into existing systems (though this has been resolved with Merge).
- Some sonographers initially expressed concerns about AI replacing their roles (though this is framed as a misconception).
- Poor image capture can lead to inaccurate annotations and measurements.
- Requires careful review and adjustment by clinicians, as the software complements, but does not replace, clinical decision-making.
- Limited information available on G2, Glassdoor, Capterra, or Reddit specifically for Us2.ai as an employer or product beyond healthcare IT reviews.
Based on reviews from: Us2.ai (User Perceptions of AI Echo), Us2.ai (How to Evaluate AI Echocardiography Platforms), Us2.ai (AI Echocardiography Reporting Software, FDA-Cleared), Merative (Integrating AI into cardiology imaging and reporting workflows for enhanced echo measurements), accessdata.fda.gov (Eko.ai Pte. Ltd. d/b/a Us2.ai K210791), Us2.ai (Clinical Evidence & Peer-Reviewed Publications), Radiology AI Tools Directory (Search FDA-cleared listings), accessdata.fda.gov (Eko.ai Pte. Ltd d/b/a Us2.ai K232835), accessdata.fda.gov (Eko.ai Pte. Ltd. d/b/a Us2.ai K250151), accessdata.fda.gov (TPLC - Total Product Life Cycle), Physician Ai Tools (DrFirst (Myndshft)), FDA (CDRH Premarket Authorizations that Used Real-World Evidence), Us2.ai (How Us2.ai and Merge Are Bringing AI Echo Directly Into Clinical Workflows), Us2.ai (AI Echo in Clinical Workflow), Indeed.com (Working at A.I: Employee Reviews)
Last updated: 2026-07-18
Videos
News, demos, and interviews about Eko.Ai Pte Ltd. D/B/A Us2.Ai.
Videos load interactively. If none appear, search YouTube for Eko.Ai Pte Ltd. D/B/A Us2.Ai →
Press & Coverage
Frequently Asked Questions
Comparisons
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]